Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

11 evidence topics · 7 sources

Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants

“Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Aldosterone, plasma renin activity, and aldosterone-renin ratio through week 48: Transform-HTN
BiomarkerPercent change in geometric mean from Launch-HTN baseline at week 48
Serum aldosterone“-54.8%”
Plasma renin activity“+123.9%”
Aldosterone-renin ratio“-79.8%”